Types of diseases mainly treated by Teritusumab/Telivac

Teritusumab (Teclistamab-cqyv) is a bispecific antibody drug that specifically targetsB cell maturation antigen (BCMA) and the CD3 receptor on T cells. As a T cell engager, it can activate T cells to kill BCMA-positive tumor cells. The drug is approved to treat relapsed or refractory multiple myeloma (RRMM), particularly when patients have failed to respond to multiple conventional treatments.

Multiple myeloma is a cancer caused by an abnormal proliferation of plasma cells in the bone marrow. It usually presents with symptoms such as bone pain, anemia, and kidney damage. As the disease progresses, patients often develop resistance to conventional treatments (such as chemotherapy, immunomodulators, proteasome inhibitors, etc.), leading to disease relapse or refractory treatment. As a targeted therapy drug, teritusumab is expected to effectively solve the limitations of traditional treatments through a bispecific mechanism.

The mechanism of action of Teritusumab works through two targets:BCMA and CD3. BCMA is a marker molecule on the surface of multiple myeloma cells and is involved in the survival and proliferation of plasma cells. By binding to BCMA, teritusumab can precisely guide T cells to the surface of myeloma cells and activate T cells to kill tumor cells. CD3 is a receptor on the surface of T cells. Teritusumab binds to the CD3 receptor on the surface of T cells, prompting T cells to participate in the immune response and enhancing the immune system's recognition and elimination of tumor cells.

Currently, teritusumab is mainly used to treat patients with relapsed or refractory multiple myeloma, especially those who have received treatments such as proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies and have experienced disease progression. According to the results of clinical trials, teritusumab has shown significant efficacy, especially for patients who have failed to respond to previous treatments or failed to maintain remission, providing a new treatment option.

Keyword tag:

Teritumumab, Telivac, Teclistamab, multiple myeloma, BCMA, CD3, immunotherapy, relapsed myeloma, refractory myeloma, T cell engagers

Reference materials:https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf